Spectrum Pharmaceuticals Inc.

09/18/2021 | Press release | Distributed by Public on 09/18/2021 07:00

ESMO Congress 2021: Efficacy and Safety of Poziotinib in Treatment-naïve NSCLC Harboring HER2 exon 20 Mutations: A Multinational Phase 2 Study (ZENITH20-4)